20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Seaport Therapeutics, Inc. Common Stock (SPTX) operates in the BIOTECHNOLOGY industry and is headquartered in Boston, United States with about 58 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, SPTX reported $0M in revenue and ($75M) in net income.
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Revenue | — | $0M | $0M |
| Operating Income (EBIT) | ($93M) | ($87M) | ($52M) |
| Operating Margin % | — | — | — |
| Net Income | ($88M) | ($75M) | ($47M) |
| Net Margin % | — | — | — |
| EBITDA | ($93M) | ($86M) | — |
| Earnings Per Share (EPS) | $-1.65 | $-1.94 | $-0.88 |
| Shares Outstanding (M) | 54M | 39M | 53M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-03-31 |
|---|---|---|---|
| Total Revenue | — | $0M | $0M |
| Operating Income (EBIT) | ($66M) | ($28M) | ($16M) |
| Operating Margin % | — | — | — |
| Net Income | ($63M) | ($25M) | ($13M) |
| Net Margin % | — | — | — |
| EBITDA | ($65M) | ($27M) | — |
| Earnings Per Share (EPS) | $-1.17 | $-0.48 | — |
| Shares Outstanding (M) | 54M | 53M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Cash from Operations (CFO) | ($46M) | ($78M) | ($30M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($46M) | ($78M) | ($30M) |
| FCF Margin % | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-03-31 |
|---|---|---|---|
| Cash from Operations (CFO) | ($26M) | ($20M) | ($20M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($26M) | ($20M) | ($20M) |
| FCF Margin % | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Assets | $442M | $249M | $316M |
| Cash & Cash Equivalents | $64M | $46M | $309M |
| Total Liabilities | $19M | $342M | $341M |
| Total Debt (Short + Long-Term) | $2M | $2M | $0M |
| Total Shareholders' Equity | $423M | ($93M) | ($25M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SPTX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms